FSM Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$462K Buy
930
+66
+8% +$29.3K 0.05% 196
2026
Q1
$386K Buy
864
+41
+5% +$19.1K 0.05% 201
2025
Q4
$373K Buy
+823
New +$355K 0.05% 203
2025
Q3
Sell
-538
Closed -$247K 334
2025
Q2
$247K Sell
538
-6
-1% -$2.77K 0.04% 240
2025
Q1
$264K Buy
+544
New +$254K 0.06% 167
2024
Q4
Sell
-439
Closed -$204K 208
2024
Q3
$204K Buy
+439
New +$211K 0.05% 184

Other funds holding VRTX

FSM Wealth Advisors's VRTX Position: Q2 2026 in Review

FSM Wealth Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 7.6% in Q2 2026, buying an estimated $29.3K and bringing the position to 930 shares worth $462K. The position accounts for 0.05% of the portfolio, ranked #196.

FSM Wealth Advisors first reported a position in VRTX in Q3 2024 and has held it in 6 quarters since. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • FSM Wealth Advisors held 930 shares of Vertex Pharmaceuticals worth $462K as of Q2 2026.
  • FSM Wealth Advisors bought 66 Vertex Pharmaceuticals shares in Q2 2026, an estimated $29.3K.
  • Vertex Pharmaceuticals made up 0.05% of FSM Wealth Advisors's portfolio in Q2 2026, its #196 holding.
  • FSM Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on FSM Wealth Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.